GB202105186D0 - Pyrrolobenzodiazepine conjugates - Google Patents

Pyrrolobenzodiazepine conjugates

Info

Publication number
GB202105186D0
GB202105186D0 GBGB2105186.7A GB202105186A GB202105186D0 GB 202105186 D0 GB202105186 D0 GB 202105186D0 GB 202105186 A GB202105186 A GB 202105186A GB 202105186 D0 GB202105186 D0 GB 202105186D0
Authority
GB
United Kingdom
Prior art keywords
pyrrolobenzodiazepine conjugates
pyrrolobenzodiazepine
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2105186.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority to GBGB2105186.7A priority Critical patent/GB202105186D0/en
Publication of GB202105186D0 publication Critical patent/GB202105186D0/en
Priority to ARP220100927A priority patent/AR125338A1/en
Priority to TW111113931A priority patent/TW202308697A/en
Priority to PCT/EP2022/059733 priority patent/WO2022218973A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
GBGB2105186.7A 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates Ceased GB202105186D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB2105186.7A GB202105186D0 (en) 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates
ARP220100927A AR125338A1 (en) 2021-04-12 2022-04-12 PYRROLOBENZODIAZEPINE CONJUGATES
TW111113931A TW202308697A (en) 2021-04-12 2022-04-12 Pyrrolobenzodiazepine conjugates
PCT/EP2022/059733 WO2022218973A2 (en) 2021-04-12 2022-04-12 Pyrrolobenzodiazepine conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2105186.7A GB202105186D0 (en) 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates

Publications (1)

Publication Number Publication Date
GB202105186D0 true GB202105186D0 (en) 2021-05-26

Family

ID=75949544

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2105186.7A Ceased GB202105186D0 (en) 2021-04-12 2021-04-12 Pyrrolobenzodiazepine conjugates

Country Status (4)

Country Link
AR (1) AR125338A1 (en)
GB (1) GB202105186D0 (en)
TW (1) TW202308697A (en)
WO (1) WO2022218973A2 (en)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (en) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd Antibiotic dc-81 and its preparation
EP1720881B9 (en) 2004-03-01 2013-04-17 Spirogen Sàrl 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
BRPI0610284A8 (en) 2005-04-21 2017-05-09 Spirogen Ltd PYROLOBENZODIAZEPINES
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
AU2011239507B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US20130330350A1 (en) 2010-11-09 2013-12-12 Medimmune, Llc Antibody Scaffold For Homogenous Conjugation
KR101412875B1 (en) 2012-10-04 2014-07-02 삼성전기주식회사 Gate driving circuit and inverter having the same
LT2839860T (en) 2012-10-12 2019-07-10 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN110452242A (en) 2012-12-21 2019-11-15 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
BR112016023436A2 (en) 2014-04-11 2017-10-17 Medimmune Llc conjugated compounds comprising cysteine engineered antibodies
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) * 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201832778A (en) 2016-11-10 2018-09-16 美商麥迪紐有限責任公司 Binding molecules specific for asct2 and uses thereof
EP3668874B1 (en) * 2017-08-18 2021-12-22 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019224340A1 (en) * 2018-05-25 2019-11-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2020006722A1 (en) * 2018-07-05 2020-01-09 Hangzhou Dac Biotech Co., Ltd Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
SG11202103424UA (en) * 2018-10-12 2021-05-28 Hangzhou Dac Biotech Co Ltd Conjugation linkers containing 2,3-diaminosuccinyl group
GB2581394A (en) * 2019-02-18 2020-08-19 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
WO2022218973A3 (en) 2022-12-22
WO2022218973A2 (en) 2022-10-20
TW202308697A (en) 2023-03-01
AR125338A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
IL269945B (en) Pyrrolobenzodiazepine conjugates
IL272625B1 (en) Pyrrolobenzodiazepine conjugates
IL284974A (en) Anti-cd228 antibodies and antibody-drug conjugates
IL287391A (en) Amatoxin antibody-drug conjugates and uses thereof
IL291486A (en) Therapeutic conjugates
IL299362A (en) Antibody-drug conjugates comprising anti-b7-h3 antibodies
IL291312A (en) Anti-ptcra antibody-drug conjugates and uses thereof
GB201902182D0 (en) Pyrrolobenzodiazepines and conjugates thereof
GB2594753B (en) Antibody-drug conjugates
GB202105186D0 (en) Pyrrolobenzodiazepine conjugates
GB202105187D0 (en) Pyrrolobenzodiazepine conjugates
EP4069297A4 (en) Anti-avb6 antibodies and antibody-drug conjugates
GB201820864D0 (en) Antibody-drug conjugates
GB201908126D0 (en) Pyrrolobenzodiazepine conjugates
GB201905117D0 (en) Pyrrolobenzodiazepine conjugates
GB201806022D0 (en) Pyrrolobenzodiazepines and conjugates thereof
IL308811A (en) Neodegrader conjugates
GB202210058D0 (en) Conjugates
GB201817088D0 (en) Pyrrolobenzodiazepine conjugates
GB201817110D0 (en) Pyrrolobenzodiazepine conjugates
GB202000121D0 (en) Compounds and conjugates
IL288681A (en) Pyrrolobenzodiazepine-antibody conjugates
IL304458A (en) Anti-egfr antibody-drug conjugates
GB201903541D0 (en) Compounds and conjugates
GB201903535D0 (en) Compounds and conjugates

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)